Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q: a Multicenter, Randomized, Double-blind, Placebo Controlled Study - QOL-ONE Rev2MDS

NCT02928419 is registered in ClinicalTrials.gov with Associazione Qol-one as lead sponsor.

NCT NCT02928419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02928419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q: a Multicenter, Randomized, Double-blind, Placebo Controlled Study - QOL-ONE Rev2MDS
Lead sponsor
Associazione Qol-one
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2015
Completion date
September 30, 2018
Enrollment
2 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes